Adjuvant polyarthritis. II. Suppression by tilorone.
Tilorone (5-35 mg/kg/day) suppressed the development of adjuvant-induced arthritis and the concurrent development of cell-mediated immune response to a secondary immunogen(EL4 cells) in a dose-related manner. Its influence on the development of the humoral immune response tp EL4 cells was found to be dependent on dosage: stimulatory at low doses (7.5 and 11.0 mg/kg/day), but inhibitory at high doses (24.0 and 35.0 mg/kg/day). Single doses of tilorone (30-300 mg/kg), administered at 24 hours or 1 hour before the injection of carrageenan, suppressed the development of acute inflammation in the rat. Evidence is presented that neither the anti-inflammatory effect of tilorone, nor its influence on the immune response could account for its antiarthritic effect. It appears plausible that the compound may act via interferon induction.
D000818:Animals; D001168:Arthritis / Q000188:drug therapy*; D001169:Arthritis, Experimental / Q000188:drug therapy*; D002460:Cell Line; D005449:Fluorenes / Q000627:therapeutic use*; D007109:Immunity / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects; D007249:Inflammation / Q000503:physiopathology; D008297:Male; D015122:Mercaptopurine / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000276:immunology; D010653:Phenylbutazone / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013994:Tilorone / Q000494:pharmacology / Q000627:therapeutic use*
D005449:Fluorenes; D015122:Mercaptopurine; D010653:Phenylbutazone; D013994:Tilorone